Zoledronic Acid and Prostate Cancer Survival
Author Information
Author(s): Hung Tzong-Tyng, Chan Jeffrey, Russell Pamela J., Power Carl A.
Primary Institution: Prince of Wales Clinical School, Prince of Wales Hospital, Randwick, New South Wales, Australia
Hypothesis
How does zoledronic acid affect bone metastasis and survival in a prostate cancer model?
Conclusion
Zoledronic acid treatment increased survival in mice with prostate cancer but did not prevent bone metastasis.
Supporting Evidence
- Zoledronic acid treatment improved survival in a dose-dependent manner.
- Mice treated with zoledronic acid had preserved bone structure compared to untreated mice.
- The number of bone metastases was similar in treated and untreated groups.
Takeaway
This study found that a drug called zoledronic acid helps mice with prostate cancer live longer, but it doesn't stop the cancer from spreading to their bones.
Methodology
Mice were injected with cancer cells and treated with zoledronic acid; bone integrity and survival were assessed.
Limitations
The study did not assess the effect of zoledronic acid on the growth of established tumors.
Participant Demographics
C57BL/6 mice, 5-6 weeks old.
Statistical Information
P-Value
p=0.031
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website